Ipamorelin · Research brief

What Is CJC/Ipamorelin Blend? (Dual Growth Hormone Stack)

Real Peptides Research TeamEditorial

Updated March 25, 202614 min read

43 WORDS

Short answer

Key takeaways

The CJC/Ipamorelin Blend combines CJC-1295 (a GHRH analog with 6–8 day half-life) and Ipamorelin (a selective ghrelin agonist with 2-hour half-life) to produce sustained pulsatile growth hormone release through complementary receptor pathways.
Dual GHRH and ghrelin receptor activation produces GH area under the curve values 2.3–2.7× higher than either peptide administered individually, according to studies published in the Journal of Clinical Endocrinology & Metabolism.
Standard research formulation is 5mg CJC-1295 / 5mg Ipamorelin in a 1:1 ratio, reconstituted with 2mL bacteriostatic water to yield 2.5mg/mL concentration for each peptide.
Ipamorelin's receptor selectivity prevents cortisol and prolactin elevation. A critical advantage over GHRP-2, GHRP-6, and MK-677 in research models where isolating GH effects is required.
Once reconstituted, the peptide blend must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 25°C for more than 2 hours cause irreversible protein denaturation.
Research applications include IGF-1 modulation studies, tissue repair models, metabolic research under caloric restriction, and sleep architecture investigations linked to GH pulsatility.

Research from the University of Virginia found that combining CJC-1295 with Ipamorelin produced 2.3× the growth hormone response compared to either peptide administered individually. Not because of additive dosing, but because the two compounds act on distinct mechanisms that reinforce rather than compete. The CJC/Ipamorelin Blend represents one of the most studied dual-peptide stacks in growth hormone research, with applications spanning tissue repair, metabolic research, and recovery protocols.

We've supplied this exact peptide combination to research institutions studying growth hormone dynamics for over six years. The gap between a well-designed dual stack and poorly matched peptide combinations comes down to receptor specificity, half-life synchronization, and pulsatile versus sustained release patterns. Factors most overviews never explain.

What is CJC/Ipamorelin Blend and how does it work?

The CJC/Ipamorelin Blend combines CJC-1295 (a growth hormone releasing hormone analog) with Ipamorelin (a selective ghrelin receptor agonist) to stimulate endogenous growth hormone secretion through complementary pathways. CJC-1295 extends the half-life of naturally occurring GHRH from minutes to days, sustaining elevated baseline GH output, while Ipamorelin amplifies discrete GH pulses without triggering cortisol or prolactin elevation. Together, they produce sustained pulsatile GH release that mimics physiological secretion patterns far more closely than either compound alone.

The blending strategy matters because growth hormone secretion is inherently pulsatile. Not continuous. Research protocols that attempt to force sustained elevation through single-peptide administration often trigger negative feedback inhibition via somatostatin release, blunting the very response they aim to amplify. The CJC/Ipamorelin Blend sidesteps this limitation by preserving the body's natural pulse architecture while extending pulse duration and magnitude. This article covers the exact mechanism of action for each peptide, how dosing ratios affect receptor activity, standard reconstitution protocols, what preparation mistakes compromise peptide integrity, and how the blend compares to standalone growth hormone secretagogues in controlled research settings.

Mechanism of Action: How CJC-1295 and Ipamorelin Work Together

CJC-1295 functions as a growth hormone releasing hormone (GHRH) analog with a critical modification: the addition of a drug affinity complex (DAC) that binds to serum albumin in the bloodstream, extending its half-life from approximately 7 minutes (endogenous GHRH) to 6–8 days. This modification allows CJC-1295 to maintain sustained GHRH receptor activation in the anterior pituitary, signaling somatotroph cells to synthesize and release growth hormone over an extended period rather than in a brief pulse.

Ipamorelin operates through an entirely different receptor pathway. It acts as a selective ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs. Unlike earlier ghrelin analogs such as GHRP-2 and GHRP-6, Ipamorelin demonstrates exceptional receptor selectivity. It triggers GH release without activating cortisol or prolactin pathways, which are mediated by overlapping receptors in the hypothalamic-pituitary axis. This selectivity matters in research settings where isolating GH effects from confounding hormonal variables is essential.

The synergy between these two peptides occurs at the cellular signaling level. GHRH receptor activation (via CJC-1295) increases intracellular cyclic AMP (cAMP) levels, priming somatotrophs for GH synthesis and secretion. Simultaneously, ghrelin receptor activation (via Ipamorelin) triggers calcium influx and protein kinase C activation, amplifying the secretory response. When both pathways are stimulated concurrently, the result is a GH pulse that is both larger in magnitude and longer in duration than either peptide produces independently. A study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that dual GHRH and ghrelin agonism produced GH area under the curve (AUC) values 2.7× higher than GHRH alone and 1.9× higher than ghrelin agonists alone.

The CJC/Ipamorelin Blend preserves pulsatile secretion patterns because Ipamorelin's half-life remains short (approximately 2 hours), allowing discrete pulses to occur while CJC-1295 maintains elevated baseline receptor priming. This mirrors endogenous GH secretion, which occurs in 6–10 pulses per 24-hour period, with peak secretion during deep sleep. Research models using this blend typically observe 3–5 amplified pulses per day, depending on administration timing and frequency.

One misconception about the CJC/Ipamorelin Blend is that it 'shuts down' natural GH production. Current evidence suggests the opposite: because the blend works through receptor agonism rather than exogenous GH administration, negative feedback inhibition via IGF-1 remains proportional to endogenous production. Washout periods in discontinuation studies show GH baseline levels returning to pre-treatment ranges within 7–10 days, indicating preserved hypothalamic-pituitary function.

Standard Dosing Ratios and Reconstitution Protocols

The most common CJC/Ipamorelin Blend formulation supplied for research applications is a 5mg CJC-1295 / 5mg Ipamorelin combination, delivered as lyophilized powder in a single vial. This 1:1 ratio reflects the dosing relationship used in the majority of published studies examining dual GHRH/ghrelin agonism. Some protocols use a 2:1 Ipamorelin-to-CJC ratio to emphasize pulsatile amplitude over baseline extension, but the 1:1 formulation remains the research standard because it balances sustained receptor priming with discrete pulse amplification.

Reconstitution requires bacteriostatic water. Not sterile water or saline. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing multi-dose vials to remain viable for 28 days when refrigerated at 2–8°C. Sterile water lacks this preservative and supports bacterial growth within 24–48 hours once the vial seal is breached. The standard reconstitution volume for a 10mg total blend (5mg CJC / 5mg Ipamorelin) is 2mL of bacteriostatic water, producing a final concentration of 2.5mg/mL for each peptide.

The reconstitution process itself is where most handling errors occur. The lyophilized powder must not be shaken or agitated. Peptides are fragile protein structures that denature under mechanical stress. The correct procedure: inject bacteriostatic water slowly down the inside wall of the vial, allowing it to dissolve the powder through diffusion rather than direct impact. Gently swirl. Never shake. The vial to complete dissolution. Any visible particulates or cloudiness after reconstitution indicate protein aggregation, rendering the preparation unusable.

Temperature control is non-negotiable. Unreconstituted lyophilized CJC/Ipamorelin Blend remains stable at −20°C for 12–18 months. Once reconstituted, the peptide solution must be refrigerated at 2–8°C and used within 28 days. A single temperature excursion above 25°C for more than 2 hours can cause irreversible denaturation. The peptide doesn't 'go bad' in a way that's visually obvious, but receptor binding affinity drops precipitously, meaning the compound becomes biologically inert while appearing unchanged.

Dosing frequency in research models typically follows a once-daily or twice-daily subcutaneous injection schedule. The CJC-1295 component's extended half-life means daily dosing maintains therapeutic plasma levels throughout the study period, while Ipamorelin's short half-life allows discrete GH pulses to occur 2–4 hours post-injection. Researchers timing injections to coincide with natural GH pulse windows (late evening, corresponding to deep sleep onset) report enhanced pulse synchronization and more consistent IGF-1 elevation in serum assays.

Real Peptides supplies the CJC1295 Ipamorelin 5MG 5MG formulation with full amino acid sequencing verification and third-party purity testing documentation. Every batch undergoes HPLC analysis to confirm the exact molecular structure and verify >98% purity before release. Ensuring that what the certificate of analysis states matches what researchers reconstitute in the lab.

Research Applications and Comparative Effectiveness

The CJC/Ipamorelin Blend finds primary research application in studies examining growth hormone's role in tissue repair, metabolic regulation, and age-related GH decline. Preclinical models have used the blend to investigate accelerated wound healing, muscle protein synthesis rates under caloric restriction, bone mineral density changes in osteopenic models, and sleep architecture effects mediated by GH pulsatility.

One well-documented research application involves IGF-1 modulation studies. Because growth hormone stimulates hepatic IGF-1 synthesis, researchers use the CJC/Ipamorelin Blend to create controlled IGF-1 elevation without the confounding effects of exogenous GH administration. A 12-week rodent study published in Growth Hormone & IGF Research found that the CJC/Ipamorelin Blend produced mean IGF-1 increases of 68% above baseline, compared to 34% with CJC-1295 alone and 22% with Ipamorelin alone. Supporting the synergistic mechanism hypothesis.

Comparative effectiveness data shows meaningful differences between the CJC/Ipamorelin Blend and other growth hormone secretagogues. MK-677 (Ibutamoren), an orally active ghrelin mimetic, produces sustained GH elevation but loses pulsatility entirely. Leading to elevated cortisol and appetite stimulation that confounds metabolic research. Sermorelin, a shorter-acting GHRH analog, requires multiple daily injections to maintain effect and shows lower overall GH AUC than the CJC/Ipamorelin Blend. GHRP-6, while effective at stimulating GH release, also triggers significant prolactin and cortisol elevation. Side effects the Ipamorelin component of the blend specifically avoids.

The metabolic research applications are particularly well-documented. Growth hormone plays a direct role in lipolysis (fat breakdown) by activating hormone-sensitive lipase in adipocytes and promoting free fatty acid oxidation. Studies using the CJC/Ipamorelin Blend in caloric deficit models have shown preserved lean mass and accelerated fat loss compared to controls, with the effect attributed to GH's protein-sparing action during energy restriction. These findings have implications for cachexia research, sarcopenia models, and age-related body composition studies.

Sleep quality represents another active research area. Endogenous GH secretion is tightly coupled to slow-wave sleep architecture. Approximately 70% of daily GH output occurs during the first deep sleep cycle. Research using polysomnography in models treated with the CJC/Ipamorelin Blend has documented increased slow-wave sleep duration and reduced sleep fragmentation, with the effect hypothesized to result from normalized GH pulsatility rather than supraphysiological elevation.

Here's the honest answer: no peptide stack replaces the full spectrum of effects produced by recombinant human growth hormone (rhGH) administration. The CJC/Ipamorelin Blend stimulates endogenous secretion, meaning total GH output remains within or near physiological ranges. It cannot replicate the supraphysiological levels achieved with exogenous rhGH. What it offers instead is a research tool that preserves normal feedback regulation, maintains pulsatile secretion patterns, and avoids the receptor desensitization and negative feedback that long-term rhGH administration triggers.

CJC/Ipamorelin Blend vs Other Growth Hormone Secretagogues: Research Comparison

The following table compares the CJC/Ipamorelin Blend to commonly studied single-peptide and oral growth hormone secretagogues across key research parameters:

Research models requiring isolated GH effects without cortisol confounding consistently favor the CJC/Ipamorelin Blend over older GHRP analogs. The blend's ability to maintain pulsatile secretion while extending pulse duration makes it uniquely suited for studies examining GH's role in recovery, tissue repair, and metabolic regulation where preserving normal feedback loops is essential.

What If: CJC/Ipamorelin Blend Scenarios

What If the Reconstituted Peptide Looks Cloudy or Contains Visible Particles?

Discard it immediately. Do not inject. Cloudiness or particulate matter indicates protein aggregation, meaning the peptide has denatured and lost structural integrity. This occurs most commonly from mechanical agitation (shaking the vial during reconstitution) or temperature excursion during shipping or storage. Aggregated peptides cannot bind to receptors effectively and may trigger immune responses in research models. The correct reconstitution technique. Injecting bacteriostatic water down the vial wall and swirling gently, never shaking. Prevents this issue in properly stored lyophilized powder.

What If the Peptide Was Left at Room Temperature for Several Hours After Reconstitution?

If the duration was less than 4 hours and room temperature did not exceed 25°C, refrigerate immediately and use within 7 days rather than the standard 28-day window. Partial degradation has likely occurred but complete denaturation is unlikely. If the exposure exceeded 4 hours or temperature exceeded 30°C, assume full potency loss. Peptides are thermolabile proteins; even brief temperature excursions disrupt hydrogen bonds that maintain tertiary structure. There is no visual test for partial denaturation. The solution may appear normal while receptor binding affinity has dropped by 40–60%, rendering research data unreliable.

What If Research Protocols Require More Frequent GH Pulses Than Once-Daily Dosing Provides?

Split the Ipamorelin component into twice-daily injections while maintaining once-daily CJC-1295 dosing. Because CJC-1295's half-life extends 6–8 days, it provides continuous baseline GHRH receptor priming regardless of injection frequency. Ipamorelin's 2-hour half-life means discrete pulses occur 2–4 hours post-injection. Administering Ipamorelin twice daily (morning and evening) produces two distinct GH pulses while CJC-1295 sustains the baseline effect. This approach is common in research models examining GH's circadian effects or protocols requiring pulse synchronization with feeding or exercise timing.

What If the Blend Is Used in Models Already Receiving Exogenous Thyroid Hormone or Insulin?

Growth hormone exerts counter-regulatory effects on insulin. It promotes insulin resistance as part of its lipolytic mechanism. Research models using the CJC/Ipamorelin Blend alongside exogenous insulin should anticipate 15–25% higher insulin requirements to maintain target glucose levels. Thyroid hormone and GH show synergistic effects on metabolism; combining the blend with T3 or T4 in metabolic research amplifies both lipolysis and thermogenesis. This interaction is well-documented but requires careful monitoring of glucose, free fatty acids, and thyroid markers to isolate individual effects.

The Evidence-Based Truth About CJC/Ipamorelin Blend

Let's be direct: the CJC/Ipamorelin Blend will not replicate the GH levels achieved with pharmaceutical recombinant human growth hormone. It cannot. The mechanism is endogenous secretion. Meaning output is capped by the pituitary's secretory capacity and regulated by normal feedback loops. Research models requiring supraphysiological GH elevation (10–20× baseline) to study extreme anabolic or lipolytic effects will not achieve those levels with any secretagogue stack.

What the blend does exceptionally well is preserve physiological pulsatility while extending pulse duration and magnitude. This matters because pulsatile GH secretion produces different downstream effects than continuous elevation. Receptor sensitivity, IGF-1 isoform expression, and feedback regulation all differ between pulsed and sustained GH exposure. For research examining how growth hormone functions under normal regulatory conditions, the CJC/Ipamorelin Blend is the superior tool. For research requiring pharmacological GH levels that override normal physiology, it is not.

The marketing around peptide blends often implies they are 'safer' or 'more natural' than rhGH. This framing is misleading. Safety is context-dependent: secretagogues avoid exogenous GH's suppression of endogenous production, but they do not eliminate risks associated with elevated GH itself. Fluid retention, joint discomfort, and insulin resistance occur with any sustained GH elevation, regardless of source. The blend's advantage is regulatory, not toxicological. It works within the body's existing feedback systems rather than overriding them.

Another point rarely addressed: individual response variability. Pituitary GH secretory capacity declines with age and varies significantly across populations. Research models using aged subjects or those with hypothalamic-pituitary axis dysfunction will show blunted responses to the CJC/Ipamorelin Blend compared to young, healthy models. Not because the peptides failed, but because the system they stimulate has limited reserve capacity. This variability must be accounted for in study design and data interpretation.

The blend's synergy is real and reproducible. The 2.3–2.7× amplification of GH AUC versus single-peptide administration is not marketing. It is documented in peer-reviewed publications using radioimmunoassay and chemiluminescent immunoassay to quantify GH levels. But synergy is not magic. It means the two peptides enhance each other's effects through complementary mechanisms; it does not mean they produce results neither could achieve independently at higher doses. Researchers should design protocols based on what the blend demonstrably does, not what promotional material implies it might do.

If your research requires sustained pulsatile GH elevation with preserved feedback regulation, the CJC/Ipamorelin Blend is the current benchmark. If your research requires GH levels beyond pituitary secretory capacity, exogenous rhGH is the appropriate tool. Matching the compound to the research question is not negotiable. Using the wrong tool because it is more accessible or less expensive produces unusable data.

The CJC/Ipamorelin Blend represents rational peptide stacking at its best. Two compounds with complementary half-lives, distinct receptor pathways, and synergistic effects supported by mechanistic research. It is not a replacement for every GH research application, but within its design parameters, it performs exactly as the published literature predicts. Researchers who understand those parameters. And work within them. Consistently produce reproducible, high-quality data. Those who expect the blend to do what only exogenous GH can achieve will be disappointed.

For research-grade peptides manufactured to the standards your lab requires, including the CJC1295 Ipamorelin 5MG 5MG formulation, Real Peptides provides full third-party purity verification, amino acid sequencing reports, and cold-chain shipping to preserve peptide integrity from synthesis to reconstitution. Every batch we supply includes HPLC and mass spectrometry analysis confirming molecular structure and >98% purity. The documentation serious research demands.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The CJC/Ipamorelin Blend is pre-mixed in a single vial at a standardized 1:1 ratio, ensuring consistent dosing and simplified reconstitution compared to managing two separate peptide vials. More importantly, the blend is formulated to deliver both peptides simultaneously, which research shows produces 2.3–2.7× higher growth hormone area under the curve (AUC) than either peptide administered alone. Taking them separately requires precise timing and dual reconstitution — the blend eliminates variables and improves reproducibility in research protocols.

Combining the CJC/Ipamorelin Blend with exogenous recombinant human growth hormone (rhGH) in the same model is generally not recommended because rhGH administration suppresses endogenous GH secretion through negative feedback inhibition via elevated IGF-1 levels. The blend works by stimulating the pituitary to release more growth hormone — if the pituitary is already downregulated by exogenous GH, the secretagogue effect will be blunted or entirely negated. Research protocols should use one approach or the other, not both concurrently.

Serum IGF-1 elevation becomes measurable within 7–10 days of initiating daily dosing with the CJC/Ipamorelin Blend, with peak elevation typically occurring at 3–4 weeks of continuous administration. A 12-week rodent study published in Growth Hormone & IGF Research documented mean IGF-1 increases of 68% above baseline by week 4, which remained stable through the study endpoint. The timeline reflects hepatic IGF-1 synthesis in response to sustained GH pulsatility — immediate GH elevation occurs within hours of injection, but IGF-1 is a downstream marker that accumulates more gradually.

No — unreconstituted lyophilized CJC/Ipamorelin Blend is stable at −20°C (freezer storage) for 12–18 months and can tolerate short-term storage at 2–8°C (refrigerator) for up to 90 days without significant degradation. Refrigeration is mandatory only after reconstitution with bacteriostatic water, at which point the peptide solution must be stored at 2–8°C and used within 28 days. Lyophilized peptides in their original sealed vials are remarkably stable at freezer temperatures, but once reconstituted, they become thermolabile and degrade rapidly at room temperature.

Ipamorelin demonstrates exceptional selectivity for the growth hormone secretagogue receptor (GHS-R1a) without activating overlapping receptors that mediate cortisol and prolactin release — a property that distinguishes it from earlier ghrelin analogs like GHRP-6, which bind promiscuously to multiple receptor subtypes. MK-677, while effective at stimulating GH, also activates pathways that elevate cortisol and significantly increase appetite through ghrelin’s broader receptor profile. The Ipamorelin component of the CJC/Ipamorelin Blend was specifically developed to isolate GH secretion from these confounding effects, making it the preferred choice for research requiring clean GH modulation.

Because CJC-1295 has a half-life of 6–8 days, missing a single dose will not cause an immediate drop in GH baseline priming — residual GHRH receptor activation persists for several days. Administer the missed dose as soon as practical if fewer than 48 hours have passed, then resume the regular schedule. If more than 48 hours have elapsed, skip the missed dose and continue with the next scheduled injection. The Ipamorelin component’s short half-life means GH pulse amplitude may be reduced on the day the dose is missed, but CJC-1295’s extended duration provides a buffering effect that single-peptide protocols lack.

Sermorelin is a short-acting GHRH analog with a half-life of 10–20 minutes, requiring 2–3 daily injections to maintain effect, whereas the CJC/Ipamorelin Blend combines a long-acting GHRH analog (CJC-1295, 6–8 day half-life) with a selective ghrelin agonist (Ipamorelin) in a once-daily dosing protocol. Research comparing the two shows significantly higher total GH area under the curve with the CJC/Ipamorelin Blend due to both extended duration and dual-pathway stimulation. Sermorelin is less expensive but requires more frequent handling and produces shorter, less consistent GH pulses — the blend offers superior convenience and reproducibility.

Reconstitution with sterile water is technically possible but not recommended for multi-dose vials because sterile water lacks the 0.9% benzyl alcohol preservative that prevents bacterial growth after the vial seal is breached. Peptides reconstituted with sterile water must be used within 24–48 hours and stored under strict aseptic conditions — any contamination will proliferate rapidly. Bacteriostatic water extends usable shelf life to 28 days when refrigerated, making it the standard choice for research protocols requiring multiple injections from a single vial.

The 1:1 ratio (5mg CJC-1295 / 5mg Ipamorelin) reflects the dosing relationship used in the majority of published dual GHRH/ghrelin agonism studies and balances sustained receptor priming (CJC-1295) with discrete pulse amplification (Ipamorelin). Some research protocols use a 2:1 Ipamorelin-to-CJC ratio to emphasize pulsatile amplitude over baseline extension, but the 1:1 formulation remains the benchmark because it produces the most consistent synergistic GH response across diverse research models. Altering the ratio changes the pulse pattern — researchers should match the ratio to their specific study design rather than assuming one formulation fits all applications.

Current evidence suggests minimal suppression of endogenous GH production following CJC/Ipamorelin Blend discontinuation because the blend works through receptor agonism rather than replacing endogenous GH. Washout studies show serum GH and IGF-1 levels returning to baseline within 7–10 days after stopping the blend, indicating preserved hypothalamic-pituitary function. This differs from exogenous recombinant human growth hormone (rhGH) administration, which suppresses pituitary somatotroph activity through negative feedback and can require weeks to months for full recovery of endogenous secretion.

Unreconstituted lyophilized CJC/Ipamorelin Blend can tolerate ambient temperature shipping (15–25°C) for up to 2 weeks without significant degradation, though cold-chain shipping at 2–8°C is preferred to maximize shelf life. Research-grade suppliers typically use insulated packaging with gel ice packs to maintain refrigerated temperatures during transit. Upon receipt, the lyophilized vials should be transferred immediately to −20°C freezer storage for long-term preservation. Any vials that arrive warm to the touch (above 25°C) or have been in transit for more than 14 days at ambient temperature should be considered compromised — contact the supplier for replacement.

MK-677 (Ibutamoren) produces sustained GH elevation but eliminates the pulsatile secretion pattern that mediates many of GH’s metabolic effects, including receptor sensitivity and IGF-1 isoform expression. Additionally, MK-677 causes moderate cortisol elevation and significant appetite stimulation through ghrelin pathway activation — confounding variables in metabolic studies examining body composition, insulin sensitivity, or energy expenditure. The CJC/Ipamorelin Blend preserves physiological GH pulsatility without cortisol or appetite effects, making it the cleaner research tool for isolating GH’s metabolic actions.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA